SecBot SecBot
Insider Cluster (6 insiders) ·Filed Aug 12, 2026

TWST

Twist Bioscience Corp
NEUTRAL
Impact 4/10
Horizondays Processed3mo ago
Insider cluster: 6 insiders, $18.1M total
Actionable Insight • Neutral

The CEO's sale is routine post-earnings option exercise and not a bearish signal given the strong fundamental backdrop. Monitor for any follow-on open-market sales by the CEO or other C-suite executives in the next 30 days. The raised guidance and 14th consecutive quarter of growth support the stock's current valuation. The cluster is neutral, no actionable trade signal.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$125.29
T+0 close · Aug 12, 2026 · via day close
Latest settled
−3.59%
T+60 · $120.79
Vs SPY
+1.88%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 13 $125.29entry
  2. T+1 · 3mo ago −5.36%α −5.17% · $118.57
  3. T+5 · 3mo ago +8.73%α +10.70% · $136.23
  4. T+20 · 2mo ago +1.54%α +3.29% · $127.22
  5. T+60 · 11d ago −3.59%α +1.88% · $120.79
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Twist Bioscience CEO Emily Leproust sold $14.2M in stock on Aug 10, 2026, following the company's strong Q3 earnings beat and raised guidance reported on Aug 3. The CEO's sale was part of a cashless exercise of 113,318 options at $26.66, with shares sold at $125.16 to cover taxes and realize gains. Director Robert Chess also sold $2.04M in a similar cashless exercise. Total insider selling of $18.14M represents 0.22% of the $8.2B market cap, which is modest in proportion. The cluster is dominated by option-exercise-related sales, not open-market liquidation of accumulated shares, reducing the bearish signal. The strong earnings beat and raised guidance provide a bullish fundamental backdrop that likely catalyzed these routine post-earnings sales.

Key Financial Metrics

Direction
selling
Total Value
$18.1M
Insiders
6

Key Facts

  • CEO Leproust sold 113,318 shares at $125.16 for $14.18M on Aug 10, 2026
  • CEO's sale was part of a cashless exercise of options at $26.66 per share
  • Director Chess sold 18,417 shares at $110.89 for $2.04M on Aug 7, 2026
  • Total insider selling of $18.14M equals 0.22% of $8.2B market cap
  • Company reported Q3 FY2026 revenue of $118.4M (+23% YoY, beat consensus) and raised FY2026 guidance to $456-457M on Aug 3, 2026
  • Gross margin expanded to 52.8% (+120 bps sequentially), 14th consecutive quarter of sequential growth

Financial Impact

Insider selling of $18.14M (0.22% of market cap) is modest; option-exercise-related sales reduce bearish signal

insider ownershipdilution

Risk Factors

  • CEO selling $14.2M could be perceived negatively by the market despite being option-exercise-related
  • If additional open-market sales by C-suite emerge in coming weeks, sentiment could shift bearish
  • Stock has rallied significantly (+23.57% on earnings day), some profit-taking by insiders is natural

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
94% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-TWST-1786565153945

US Market Status

Market Closed · Opens Wed (14h 25m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 12, 2026